|
- Regeneron | Pushing the Bounds of Science
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines Join our team and explore clinical trials
- Regeneron Pharmaceuticals - Wikipedia
On February 4, 2020, the U S Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19
- PUSH THE BOUNDS OF SCIENCE - Regeneron
Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases
- Regenerons experimental therapy combo effective in untreated cancer . . .
Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the
- About Regeneron | Our Company
We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® (RGC) and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases
- ASH: Regeneron eyes simpler regimens in bid to move bispecifics into . . .
In essence, Regeneron is trying to move Lynozyfic and odronextamab into earlier lines of treatment by testing less onerous regimens than its rivals in the space
- Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin Moreover, as of September 30, Regeneron had about $2 2 billion remaining under its authorized share
- Regeneron inks gene editing deal with startup Tessera
Regeneron Pharmaceuticals is putting more money into gene editing, announcing Monday a partnership with Tessera Therapeutics to develop an experimental program for a rare liver and lung disease At the center of the deal is a treatment Tessera, a well-funded startup backed by Flagship Pioneering, is developing for alpha-1 antitrypsin deficiency Regeneron is paying Tessera $150 million upfront
|
|
|